{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.92","value":"51.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Time to response is defined as the time from the date of first administration of study treatment to the date of first documented evidence of CR or nCR or PR (whichever status is recorded first). Patients who do not have a response of PR or better by the data cut-off date are censored.","dispersionType":"Standard Deviation","groups":[{"description":"panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma","id":"OG000","title":"Panobinostat + Bortezomib & Dexamethasone"}],"paramType":"MEAN","populationDescription":"FAS","reportingStatus":"POSTED","timeFrame":"after eight cycyles of treatment (24 weeks)","title":"Time to Response (Greater Than or Equal to PR) Based on Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Days"}